Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

This is an interventional other trial for COPD Read More

Main Inclusion Criteria:

• Subjects have read, understood, and signed the written informed consent form (ICF)
• Diagnosis of COPD GOLD Stage 1 or 2 (FEV1/FVC <0.7 & FEV1 ≥60% predicted [post-BD])
• History of chronic bronchitis symptoms (sputum and cough) over the previous 12 months assessed by CAT1 and CAT2 scores ≥ 3
• Body mass index (BMI) 17.6-40.0 kg/m2 and body weight > 50 kg (male) or 40 kg (female).
• Subject has a smoking history of at least 10 years.
• Subject has been smoking ≥ 10 commercially available cigarettes/day on average (no brand restriction) for at least 1 year prior to V1 (based on self-reporting).
• Subject has not used other tobacco and nicotine products apart from cigarettes on a daily basis over the past year prior to V1.
• For subjects not willing to quit smoking only: have been advised to quit smoking, informed of smoking risks and of cessation programs and is still not willing to quit during the study duration.
• Subjects willing to quit smoking only: willing to set a target quit date (TQD) within the next 28 days at V1 as assessed by self-reported questions.

Main Exclusion Criteria:

• Subjects with any (mild, moderate or severe) COPD exacerbation that has not resolved at least four weeks prior to V1
• Subjects with other relevant pulmonary diseases than COPD. No new examination is required if the subject can present at V1, a Chest X-Ray (CXR) not older than 6 months with anterior-posterior and left lateral views
• Subjects with pneumonia or other lower respiratory tract infections that have not resolved at least four weeks prior to V1
• Subjects with other active systemic infections that have not resolved at least 4 weeks prior to V1
• Subjects with other active respiratory disorders: tuberculosis, lung cancer, bronchiectasis, sarcoidosis, asthma, pulmonary hypertension, interstitial lung diseases (e.g., idiopathic pulmonary fibrosis [IPF]), or other active pulmonary diseases during the screening period (V1 to V2)
• The subject is confirmed or suspected with active SARS-CoV-2 infection (as per site and per country recommendation)
• Clinically significant ECG alterations that will not allow subject to participate in the study, per Investigator's discretion
• Any concomitant disease that in the opinion of the investigator would interfere with the study procedures
• Subjects with diagnosed alpha-1 antitrypsin deficiency (AATD)
• History of alcohol and / or drug abuse (other than tetrahydrocannabinol [THC]).
• Positive serology test (HIV 1/2, hepatitis B or C).
• Inability to cooperate with the study procedures
• Previous participation in this study, or participation in an investigational study (drug or medical device) within 4 weeks before V1 (participation in observational studies/registries allowed)
• Close affiliation with the investigational site: a close relative of the investigator, a person dependent on the investigational site (e.g., employee or student of the investigational site)
• Subject is a current or former employee of the tobacco industry or their first-degree relatives (parent, child, spouse)
• Subjects have re-initiated smoking in the six months prior to V1
• Subjects have used in the past 3 months, or are currently daily using THS
• Any oral or injectable corticosteroids (acute or chronic treatments) in the 2 months preceding V1, excluding short term use for a COPD exacerbation.
• Female subject is pregnant or breastfeeding, (a urine pregnancy test will be performed at V1 and V2)
• For women of childbearing potential, female subject who does not agree to using an acceptable method of effective contraception during the entire study.